Maria Julia Marques

• Abstract

  Duchenne muscular dystrophy (DMD) is a progressive degenerative disease that affects skeletal and cardiac muscles, leading to death due to cardiorespiratory failure. Although there is no cure for this disease, recent gene and drug therapies are being able to slow down the progression of the disease, improving life quality and duration. So far, corticoids, such as deflazacort, are still th…

  G-protein coupled receptors and autophagy: potential targets of omega-3 and deflazacort in DMD therapy, AP.R

• Abstract

  Duchenne muscle dystrophy (DMD) is a progressive degenerative disease that affects skeletal and cardiac muscles, leading to death by the age of 25 due to cardiorespiratory failure. Although there is no cure for this disease, recent gene and drug therapies are being able to slow down the progression of the disease, improving life quality and duration. The need for new biomarkers to better …

  Pre-clinical studies in the mdx mouse: metabolomics, biomarkers and omega-3 therapy, AP.R

• Abstract

  Duchenne muscular dystrophy (DMD) is the most common childhood myopathy, characterized by muscle loss and cardiorespiratory failure. While the genetic basis of DMD is well established, secondary mechanisms associated with dystrophic pathophysiology are not fully clarified yet. In order to obtain new insights into the molecular mechanisms of muscle dystrophy during earlier stages of the di…

  Isobaric tagging-based quantification for proteomic analysis: a comparative study of spared and affected muscles from mdx mice at the early phase of dystrophy, PUB.ART

(Only some records are available in English at this moment)

• Abstract

  Biological markers are cellular, structural and biochemical quantifiable components that can be used as parameters to evaluate the presence and progression of a disease or the effect of a treatment. Duchenne muscular dystrophy (DMD) is a progressive degenerative disease that affects the skeletal and cardiac muscles leading the patient to death by cardiorespiratory failure. Whereas several…

  Biomarkers of Duchenne muscular dystrophy: metabolomic and immunoassay study in patients and in mdx mice, BP.PD

• Abstract

  In Duchenne Muscular Dystrophy (DMD) and in the mdx mice, model of DMD, lack of dystrophin leads to skeletal and cardiac muscle loss, fibrosis and progressive cardiorespiratory failure. Biomarkers for DMD have been widely investigated to follow up the evolution of the disease, facing the new pharmacological, genetics and cellular therapies to DMD. In the present study, by using metabolomi…

  Biomarkers of cardiomyopathy in dystrophy: a metabolomic study and pharmacological therapy, BP.DR

• Abstract

  The Duchenne Muscular Dystrophy (DMD) is the most severe of dystrophinopathies and results of non-expression of dystrophin in skeletal and cardiac muscle. The inflammatory response is exacerbated and seems to contribute to the progression of the disease leading to fibrosis and impairing muscle regeneration. In the dystrophic mice mdx distinct populations of macrophages (M1-M2-Th1 and Th2)…

  Pharmacological therapy of the dystrophinopathies: fibrosis and muscular regeneration in mdx mice treated with omega-3, BP.DR

(Only some records are available in English at this moment)